In this analysis including 29 340 individuals from RESPOND and 1078 cancer events, the incidence of cancer decreased as cumulative INSTI exposure increased in ART-naive individuals, however there was no association between cancer risk and INSTI exposure in ART-experienced individuals. Background Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n = 113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (<= 6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P = .60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P < .0001). Conclusions Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting / L. Greenberg, L. Ryom, B. Neesgaard, J.M. Miró, L. Dahlerup Rasmussen, R. Zangerle, K. Grabmeier-Pfistershammer, H.F. Günthard, K. Kusejko, C. Smith, C. Mussini, M. Menozzi, F. Wit, M. Van Der Valk, A. d'Arminio Monforte, S. De Wit, C. Necsoi, A. Pelchen-Matthews, J. Lundgren, L. Peters, A. Castagna, C. Muccini, J.J. Vehreschild, C. Pradier, A. Bruguera Riera, A. Sönnerborg, K. Petoumenos, H. Garges, F. Rogatto, N. Dedes, L. Bansi-Matharu, A. Mocroft. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 9:3(2022 Mar), pp. ofac029.1-ofac029.11. [10.1093/ofid/ofac029]
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
A. d'Arminio Monforte;
2022
Abstract
In this analysis including 29 340 individuals from RESPOND and 1078 cancer events, the incidence of cancer decreased as cumulative INSTI exposure increased in ART-naive individuals, however there was no association between cancer risk and INSTI exposure in ART-experienced individuals. Background Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n = 113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (<= 6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P = .60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P < .0001). Conclusions Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ofac029.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
419.01 kB
Formato
Adobe PDF
|
419.01 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
